50 results about "Tumor proteins" patented technology

The invention discloses a polypeptide and application thereof in preparation of a medicine for preventing and / or treating cancers. The amino acid sequence of the polypeptide is shown as SEQ ID No. 1 or SEQ ID No. 2. The cancer is at least one of breast cancer, colorectal cancer, leukemia, esophageal cancer, pancreatic cancer, brain glioma, kidney cancer, skin cancer, osteosarcoma, ovarian cancer and prostate cancer. The invention designs and synthesizes the polypeptide of a targeted staphylococcus tumor protein compound SND1-MTDH containing a nuclease structural domain 1 (SND1 and a heteromucin (MTDH), finds that the polypeptide has excellent inhibitory activity on various different types of human cancer cells for the first time, and provides an optional scheme for broad-spectrum anti-cancer drugs. The polypeptide applied in the invention is simple in synthesis process and low in production cost.

The present invention provides small molecule inhibitors of KRAS (G12D) mutant oncoproteins having the structural formula R00F2C-L-R0, as well as pharmaceutically acceptable salts and compositions thereof, which are useful for the treatment of cancer and related conditions.

The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the Si subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transporting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteria, viruses and even tumors.

The invention relates to the technical field of medical image processing and analysis, and discloses an oncoprotein quantitative evaluation method and system based on image recognition, and the method comprises the steps: obtaining a panoramic digital image of an IHC slice, extracting a region of interest in the panoramic digital image, segmenting the region of interest to obtain high-resolution image blocks, and carrying out the segmentation of the high-resolution image blocks; inputting the high-resolution image blocks into a pre-trained FCN model, outputting a preliminary positive region, performing SAPD algorithm optimization according to the preliminary positive region to obtain a positive region, performing parameter extraction on the positive region to obtain the pixel number of an MAFG positive region, the pixel number of an HMOX1 positive region and the area of a single pixel, and based on the pixel number of the MAFG positive region, the pixel number of the HMOX1 positive region and the single pixel area, carrying out calculation to obtain tumor protein quantitative analysis parameters. The method can realize quantitative evaluation of oncoprotein.

The invention provides a puncture sample detection platform based on a tumor protein targeting probe. According to the puncture sample detection platform, IR-780 is used for marking tumor specific protein in a puncture sample; the improved three-dimensional gel electrophoresis device is used for separating proteins in tissues; the gel processing platform is used for processing and analyzing the separation gel medium; and the automatic diagnosis platform is used for automatically judging benign and malignant conditions of the puncture sample according to the intensity and coherence of the fluorescence signal and circling the contour of the malignant sample. Compared with clinical pathological examination, the method has the advantages that benign and malignant puncture samples are judged by evaluating the protein content of various tumor receptors, and the problem of diagnosis difficulty caused by limited histological information is well solved. Meanwhile, the dependence on visual diagnosis of pathological analysis of the frozen section and experience of pathologists is reduced, and the accuracy and efficiency of pathological tissue diagnosis are effectively improved. The automatic diagnosis platform can eliminate a large number of benign samples and can reduce repeated work of pathologists.

The invention discloses a gallbladder malignant tumor protein diagnosis biomarker combination, a kit and application. The protein marker provided by the invention comprises CA1 and / or IGFBP6 (insulin-like growth factor binding protein 6). According to the invention, an LC-MS / MS mass spectrometry method is adopted, mass spectrometry is carried out on a large number of clinical plasma samples, and by calculating log2 difference multiples of corresponding protein molecule contents in the plasma of a gallbladder cancer patient and the plasma of a normal person, it is determined that two protein molecules (CA1 protein and IGFBP6 protein) have good inspection benefits; the kit can be used as a marker for early diagnosis of gallbladder cancer; therefore, the invention provides a non-invasive screening means based on plasma, and the non-invasive screening means is used for predicting the cholecystic malignant tumor and distinguishing the cholecystic carcinoma crowd from the non-cancer crowd. And materials are convenient to take, the blood sample amount is small, and the sensitivity is high. The invention can fill the blank that no protein marker combination with high diagnostic efficiency exists at present for the cholecystic malignant tumor, and has great clinical significance.

A system and method for preparing a cancer vaccine (and optionally purifying the blood) has a blood filtration system, controlled by a processing unit, for filtering exogenous blood plasma to isolate tumor cells, tumor stem cells and tumor breakdown products. The blood filtration system filter may include multiple layers having differently sized apertures to retain differently sized materials (from among tumor cells of different sizes, tumor stem cells and tumor breakdown products. A device directs electromagnetic radiation at the separated tumor cells, tumor stem cells and / or tumor breakdown products. The electromagnetic radiation may cause the separated tumor cells, separated tumor stem cells and / or separated tumor breakdown products (for example tumor protein such as DNA and / or tumor exosomes) to have a coagulated outer layer such as by degrading the outer surface. The electromagnetic radiation may have a UV wavelength. A conical coil improves flow rate uniformity. Tumor exosomes may be centrifuged.

The invention provides an application of punicalin (PNC) in preparation of antitumor drugs, and belongs to the technical field of biological medicines related to tumor diseases. The tumor proteins TNC and FLNC can jointly promote endothelial-mesenchymal transition (EndMT). The PNC is a bimolecular targeting natural inhibitor of tumor proteins TNC and FLNC. The PNC can inhibit the expression of EndMT related protein, multidrug resistance related membrane protein and collagen related protein through targeted inhibition of TNC and FLNC, so that the sensitivity of drug-resistant tissues to chemotherapeutic drugs is recovered. The PNC can be developed into a universal EndMT and collagen pathway targeting drug for reversing tumor drug resistance, combined chemotherapy drugs are developed from the aspects of tumor microenvironment endothelial cells, ECM deposition and the like so as to improve drug sensitivity, and the PNC has important clinical significance in tumor resistance.

Provided herein are methods for producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

To provide methods of treating cancer.SOLUTION: Disclosed herein is a method for treating cancer by administering a heterologous prime-boost regimen of an oncolytic microorganism that enhances or elicits an immune response to a tumor protein not encoded by the oncolytic microorganism. The method provided herein includes a method for eliciting or enhancing immune response in vivo in a subject. The methods described herein feature, inter alia, methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.SELECTED DRAWING: None

The continuous culture of a Schizosaccharomyces yeast containing a nucleic acid construct which contains a translationally controlled tumor protein (TCTP) gene promoter derived from a Schizosaccharomyces yeast, and a polynucleotide fragment, and in which the polynucleotide fragment is artificially linked to the downstream of the promoter to be expressed under the control of the promoter, allows the polynucleotide fragment under the control of the promoter to be highly expressed.

The invention relates to the technical field of pathological diagnosis, in particular to a tumor grading detection system based on holoproteome cysteine reactivity analysis, which comprises an in-situ labeling module, an in-situ detection module and an in-situ detection module, the histological separation module is used for carrying out molecular weight layering separation on the labeled tumor protein and counting the fluorescence signal intensity of each layer; the processing and analysis module is used for constructing a proteome-level cysteine reactivity map with position resolution capability; the tumor grading module is used for carrying out normalization processing on the average fluorescence intensity of each layer and the highest signal layer to obtain normalized intensity T, drawing a component specificity risk curve by taking the number of layers as a horizontal coordinate, and recording the area under the curve as the normalized intensity T as TSI; the TSI is in positive correlation with the tumor malignancy degree and serves as the basis of tumor grading. The method can accurately diagnose a tumor positive area, and the specificity and the sensitivity are both 100%.

Disclosed herein are polypeptide fragments and polynucleotides based on mutant capicua transcriptional repressor (CIC), catenin beta 1 (CTNNB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog B (ERBB2), kirsten rat sarcoma (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), splicing factor 3b subunit 1 (SF3B1), SRY-box transcription factor 17 (SOX17), tumor protein 53 (TP53), and cytomegalovirus (CMV) sequences, vectors, host cells, viruses, methods for generating CD8+ T-cells, and methods of treatment. Also disclosed herein are T-cell receptors (TCRs), polynucleotides, vectors and cells comprising the TCRs, and methods of treatment.

The invention discloses application of Wilms oncoprotein-1 (WTAP) related protein in rheumatoid arthritis, finds that the specific expression level of WTAP in RA is increased for the first time, and finds that the WTAP regulates the polarization reaction of macrophages in a targeted manner so as to regulate the inflammation level of RA through overexpression and interference of WTAP and detection and verification of a WB method and an RT-qPCR method. Therefore, the preparation for detecting Wilms oncoprotein-1 (WTAP) related protein can be used for preparing a rheumatoid arthritis diagnosis preparation. The invention verifies the correlation between WTAP and RA inflammatory response and the regulation function on inflammation, and the WTAP has higher detection sensitivity and specificity on RA disease activity, and can be used for evaluating RA disease progression and relieving RA inflammatory response.

TCR and peptide. T cell receptor (TCR) that binds the Wilms tumor 1 protein (WT1) peptide when presented by the major histocompatibility complex (MHC).

This invention discloses a polypeptide that specifically binds to the RNA-binding domain of the PRMT5 protein and its applications, belonging to the field of biomedical technology. The polypeptide specifically binds to the RNA-binding domain of the PRMT5 protein, and its amino acid sequence includes sequence A or sequence B. Sequence A is: LTNKKGFPVLSK; sequence B is: PGMFSWFPILFP. This polypeptide can precisely interfere with PRMT5-RNA interaction without affecting PRMT5 protein abundance, thereby specifically disrupting a key pathway for maintaining tumor protein translation. This polypeptide therapeutic agent has been shown to effectively inhibit tumor growth in preclinical models, validating the therapeutic feasibility of the "PRMT5-RBD targeting" strategy and providing a novel potential treatment option for patients (including those insensitive to or resistant to existing methylation inhibitors).

The present invention provides an impedance biosensor based on immunoaffinity and its preparation method and application. The preparation method includes: surface modification using mercaptopropionic acid or chitosan based on a wireless passive sensor, or surface modification using nitrocellulose membrane based on a three-electrode sensor, and then binding a probe that can capture tumor protein markers on the surface to prepare an impedance biosensor based on immunoaffinity. The present invention provides for the first time such a preparation method of an impedance biosensor based on immunoaffinity and its application in tumor protein marker detection. Compared with the preparation method of traditional biosensors, the method of the present invention can ensure the high density, integrity and number of effective binding sites of biological molecules, realize the detection of trace proteins of tumor proteins, and the detection limit reaches the pg level. At the same time, it can also help solve the problem of accurate calibration of protein markers, and has the advantages of low detection cost and short detection cycle.

The application belongs to the field of electrochemistry, and relates to tumor protein P53 gene detection, in particular to a label-free double-color test strip, a kit and a preparation method thereof for tumor protein P53 gene detection. The application belongs to a novel LFA method, which combines DNA hybridization chain reaction with the electrostatic adsorption principle of test line / control line, selects common and cost-effective bovine serum albumin as the test line, utilizes the difference in the adsorption capacity of BSA to double-stranded DNA and nano-gold, and the different flow rates of different molecules on the NC membrane to complete the detection of p53 at different concentrations. The test line is constructed by positively charged PDDA to ensure the effectiveness of the LFA. Meanwhile, the detection principle of a liquid colorimetric sensor is combined, and the double-color development greatly reduces the detection limit of the test strip. The sensor is label-free throughout, and has high analytical performance in terms of sensitivity, selectivity and practicability. The p53 gene is detected on the lateral flow test strip for the first time.

The present disclosure, in some aspects, provides Co-stimulatory Conditional Bispecific Redirected Activation constructs, or “co-stim COBRA,” that are administered in an active prodrug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well and immune cells (e.g., one or more types of immune cells), thus recruiting immune cells to tumor, resulting in treatment.

The invention relates to an autologous cancer vaccine and its preparation method. The autologous vaccine according to the present invention is based on hydroxyapatite and / or tricalcium phosphate particles onto which tumor proteins are adsorbed, these tumor proteins being enriched in HSP110.

Disclosed herein are methods of treating cancer by administering a heterologous prime-boost regimen of oncolytic microorganisms that enhances or elicits an immune response to a tumor protein that is not coded for by the oncolytic microorganisms.

Methods of treating a cancer comprising a mutation in tumor protein p53 (TP53) or DNA mismatch repair protein Mlhl (MLH1) comprising: determining the cancer comprises the mutation and administering an agent that decreases abundance or function of a protein synthetically lethal with TP53 or MLH1 are provided. Agents that decrease abundance or function of a protein synthetical lethal with TP53 or MLH1 for use in treating a cancer comprising a mutation in TP53 or MLH1 are also provided.

A PET / SPECT probe includes the following formula:P-L-Cwherein P is a EDB-FN targeting peptide, C is a PET / SPECT contrast agent; and L is an optional linker that covalently links the peptide to the contrast agent.

In certain aspects, provided herein are therapeutic compositions comprising an mRNA formulated in a lipid nanoparticle (LNP), wherein the mRNA comprises an open reading frame encoding p53 polypeptide, and methods of using the same.

The invention discloses a target protein degradation agent based on ethacrynic acid and application thereof, relates to the technical field of drug development, and comprises a target protein degradation agent based on ethacrynic acid, which has a structure as shown in the following formula (I): R1LR2 formula (I), wherein R1 is ethacrynic acid EA; r2 is a ligand JQ1 of a bromodomain protein 4; l is a connecting chain, and R1 and R2 are connected through L; according to the target protein degradation agent based on ethacrynic acid and the application thereof, E3 ubiquitinase HECTD1 is recruited through ethacrynic acid to realize degradation of target protein BRD4, and the process is realized through ubiquitin-proteasome, so that drug resistance caused by target mutation is avoided, a new choice is provided for recruiting molecules of the target protein degradation agent, and the target protein degradation agent has the advantages that the target protein degradation agent is simple and convenient to operate, and the application prospect is wide. Meanwhile, a new E3 ubiquitination enzyme is also provided, a new construction thought is provided for a degradation agent of tumor protein difficult to target, and the E3 ubiquitination enzyme has good application in preparation of anti-cancer drugs.

A novel binding molecule or a fragment thereof and uses thereof are disclosed. The novel binding molecule or a fragment thereof specifically bind to an extracellular translationally controlled tumor protein (TCTP). The binding molecule and the fragment thereof can be used to diagnose, treat, or prevent cancer. The binding molecule and the fragment thereof can be used to alleviate or prevent immune suppression in a tumor immune microenvironment. The binding molecule and the fragment thereof can be used to diagnose, treat, or prevent cancer in a patient who has no response, has a limited response, or is likely to have such a response to treatment using a cancer immunotherapeutic agent.

The present invention aims to identify regulatory factors of the cancer immune microenvironment and to provide methods for the therapeutic use of these regulatory factors. [Solution] Specifically, the present invention is an inhibitor of the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor immune microenvironment (TIME), comprising as an active ingredient a substance that suppresses or inhibits the function of immunomodulatory factors released from tumor dead cells. More specifically, the inhibitor comprises, for example, a substance that suppresses or inhibits the function of TCTP (translationally controlled tumor protein).

To induce cancer cell death, cancer cells are selected that express estrogen-receptor β (ERβ) and mutant tumor protein 53 (TP53). An agent that increases ERβ protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERβ and mutant TP53, an agent that increases ERβ protein expression is administered to induce cell death in the cancer cells. To increase estrogen receptor β (ERβ) expression levels in a subject having low ERβ expression levels, tamoxifen is administered to increase ERβ protein levels in the subject. To treat a subject having cancer cells expressing estrogen-receptor β (ERβ) and wildtype tumor protein 53 (TP53), an agent that inhibits ERβ and TP53 binding interaction is administered to induce cell death in the cancer cells of the subject.

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

To provide new Wilms tumour 1 protein (WT1) epitopes, particularly WT1 epitopes restricted to common HLA alleles, and new T-cell receptors (TCRs) that bind to WT1 peptides when presented by a major histocompatibility complex (MHC).SOLUTION: A novel WT1 epitope, and a TCR comprising a specific amino acid sequence in the CDR region responsible for binding specificity to WT1, are provided. Moreover, T-cells expressing TCRs, capable of specifically targeting and killing cells that overexpress the WT1 protein, are also provided.SELECTED DRAWING: None